ProQR Therapeutics Advances AX-0810 Towards Clinic
Ticker: PRQR · Form: 6-K · Filed: Nov 3, 2025 · CIK: 1612940
| Field | Detail |
|---|---|
| Company | Proqr Therapeutics N.V. (PRQR) |
| Form Type | 6-K |
| Filed Date | Nov 3, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-update, drug-development, biotech
TL;DR
ProQR Therapeutics hosted an event on Nov 3, 2025, to update investors on AX-0810's clinical trial readiness.
AI Summary
On November 3, 2025, ProQR Therapeutics N.V. hosted a virtual event to discuss the progress of their drug candidate AX-0810. The event focused on establishing the safety, pharmacokinetic profile, and biomarker response of AX-0810, indicating a step towards clinical trials.
Why It Matters
This event signals ProQR's progress in developing AX-0810, a potential new treatment, and provides investors with an update on its clinical development path.
Risk Assessment
Risk Level: medium — The filing indicates progress in drug development, which inherently carries clinical and regulatory risks, but doesn't disclose significant financial or operational changes.
Key Players & Entities
- ProQR Therapeutics N.V. (company) — Registrant
- AX-0810 (drug_candidate) — Drug candidate discussed at event
- November 3, 2025 (date) — Date of the analyst and investor event
FAQ
What was the primary purpose of the virtual analyst and investor event hosted by ProQR Therapeutics N.V. on November 3, 2025?
The event was held to discuss the progress of AX-0810, focusing on establishing its safety, pharmacokinetic profile, and biomarker response, in preparation for clinical trials.
What is the name of the drug candidate that ProQR Therapeutics N.V. is advancing?
The drug candidate is named AX-0810.
What key aspects of AX-0810 were discussed at the November 3, 2025 event?
The event focused on establishing the safety, pharmacokinetic (PK), and biomarker response of AX-0810.
What form is ProQR Therapeutics N.V. required to file annually?
ProQR Therapeutics N.V. is required to file annual reports under cover of Form 20-F.
Where is ProQR Therapeutics N.V. located?
ProQR Therapeutics N.V. is located at Zernikedreef 9, 2333 CK Leiden, The Netherlands.
Filing Stats: 301 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2025-11-03 16:01:51
Filing Documents
- tm2529990d1_6k.htm (6-K) — 11KB
- tm2529990d1_ex99-1.htm (EX-99.1) — 47KB
- tm2529990d1_ex99-1img001.jpg (GRAPHIC) — 184KB
- tm2529990d1_ex99-1img002.jpg (GRAPHIC) — 126KB
- tm2529990d1_ex99-1img003.jpg (GRAPHIC) — 304KB
- tm2529990d1_ex99-1img004.jpg (GRAPHIC) — 100KB
- tm2529990d1_ex99-1img005.jpg (GRAPHIC) — 125KB
- tm2529990d1_ex99-1img006.jpg (GRAPHIC) — 99KB
- tm2529990d1_ex99-1img007.jpg (GRAPHIC) — 98KB
- tm2529990d1_ex99-1img008.jpg (GRAPHIC) — 177KB
- tm2529990d1_ex99-1img009.jpg (GRAPHIC) — 120KB
- tm2529990d1_ex99-1img010.jpg (GRAPHIC) — 130KB
- tm2529990d1_ex99-1img011.jpg (GRAPHIC) — 163KB
- tm2529990d1_ex99-1img012.jpg (GRAPHIC) — 150KB
- tm2529990d1_ex99-1img013.jpg (GRAPHIC) — 151KB
- tm2529990d1_ex99-1img014.jpg (GRAPHIC) — 149KB
- tm2529990d1_ex99-1img015.jpg (GRAPHIC) — 163KB
- tm2529990d1_ex99-1img016.jpg (GRAPHIC) — 183KB
- tm2529990d1_ex99-1img017.jpg (GRAPHIC) — 148KB
- tm2529990d1_ex99-1img018.jpg (GRAPHIC) — 116KB
- tm2529990d1_ex99-1img019.jpg (GRAPHIC) — 134KB
- tm2529990d1_ex99-1img020.jpg (GRAPHIC) — 126KB
- tm2529990d1_ex99-1img021.jpg (GRAPHIC) — 119KB
- tm2529990d1_ex99-1img022.jpg (GRAPHIC) — 122KB
- tm2529990d1_ex99-1img023.jpg (GRAPHIC) — 100KB
- tm2529990d1_ex99-1img024.jpg (GRAPHIC) — 109KB
- tm2529990d1_ex99-1img025.jpg (GRAPHIC) — 124KB
- tm2529990d1_ex99-1img026.jpg (GRAPHIC) — 94KB
- tm2529990d1_ex99-1img027.jpg (GRAPHIC) — 113KB
- tm2529990d1_ex99-1img028.jpg (GRAPHIC) — 177KB
- tm2529990d1_ex99-1img029.jpg (GRAPHIC) — 55KB
- tm2529990d1_ex99-1img030.jpg (GRAPHIC) — 136KB
- tm2529990d1_ex99-1img031.jpg (GRAPHIC) — 76KB
- 0001104659-25-105534.txt ( ) — 5804KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PROQR THERAPEUTICS N.V. Date: November 3, 2025 By: /s/ Dennis Hom Dennis Hom Chief Financial Officer INDEX TO EXHIBITS Number Description 99.1 Presentation of ProQR Therapeutics N.V. for November 3, 2025 Analyst and Investor Event.